Our previous studies have demonstrated that carriers of CYP2C19 loss-of-function (LOF) alleles are associated with clopidogrel resistance, greater risk of stroke and composite vascular events than noncarriers among patients with IS or transient ischemic attack (TIA) treated with clopidogrel [9, 13]. This evidence concerns the gene CYP2C19 and stroke disorder.